Back to search results

Remote Temperature Monitoring for Cancer Patients at Risk of Fever

This study is looking at whether using a wearable thermometer for 24/7 remote temperature monitoring can help cancer patients who are at risk of developing a fever after chemotherapy. Researchers want to see if this monitoring reduces the number of days patients spend in the hospital. They also want to understand the costs involved and how many billing codes are generated. You might be able to join if you are 18 or older, at risk of fever after discharge, and have a smartphone (iOS or Android) or are willing to use one provided by the study. The study aims to enroll 150 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 150 participants. It will compare patients who consistently use remote temperature monitoring with those who do not.
What's involved
You would use a wearable thermometer for 24/7 remote patient monitoring and install the TempShield app on your phone. You would also allow the study to send text reminders for temperature checks or surveys.
Compensation
Not stated in the trial record.
Follow-up
Your participation will be monitored from the day you enroll until a maximum of 180 days after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06752512

Remote Temperature Monitoring of Patients At Risk for Developing Fever

Recruiting
NAAges 18+InterventionalDiagnostic
AION Biosystems
~150 participants
Updated 2024-12-30 on ClinicalTrials.gov
What's tested:Remote Patient Monitoring

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean number of inpatient days
Measured over Day of enrollment to the end of participation in the study, a maximum of 180 days after enrollment

Conditions

Fever
Cancer
Remote Patient Monitoring

Explore related trials

FeverMalignant Neoplasm

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Tallat Mahmood, M.D. · PRINCIPAL_INVESTIGATOR · Ellis Hospital

Who to contact

David Colburn, Ph.D.
[email protected]
(757) 641-2019
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject is at risk of a fever post discharge.
Subject is ≥ 18 years or older.
Subject has an iOS or Android phone, or is able to operate an AION provided smartphone device.
Subject is willing to install the TempShield app on his/her phone.
Subject is willing to allow AION to send text reminders to take temperature or complete surveys.
Subject is willing to take an oral temperature as directed by their care plan.
Subject is willing to configure the phone to ensure these notifications are delivered, even when phone is in a "no notification" mode.
Subject or subject caretaker is able and willing to complete subject surveys.
Subject is willing and able to provide written informed consent in English.
Subject is willing and able to comply with all program procedures, requirements, assessments, visits, and complete questionnaires.
English speakers

Exclusion

Unable to provide informed consent
Subjects with a history of Medical Adhesive-Related Skin Injury (MARSI)
Subjects with no available placement that avoids open wounds or traumatized skin (burns. Blisters. Etc.)
Non-English speakers: The mobile application is only currently available in English. Future development will include other languages.
Subjects receiving prophylactics that could induce fever.
Subjects with a silicon allergy
Subject does not have iOS or Android phone, and is unable to operate an AION provided smartphone device.
Subjects who are not willing to take an oral temperature per their care plan.

What this trial measures

  • Mean number of inpatient daysDay of enrollment to the end of participation in the study, a maximum of 180 days after enrollment

    The number of days the participant was admitted to a hospital while receiving remote patient monitoring